128 related articles for article (PubMed ID: 34334634)
1. Risk Factors for Tumor Positive Resection Margins After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Results From the Dutch Upper GI Cancer Audit: A Nationwide Population-Based Study.
Defize IL; Goense L; Borggreve AS; Mook S; Meijer GJ; Ruurda JP; van Hillegersberg R;
Ann Surg; 2023 Feb; 277(2):e313-e319. PubMed ID: 34334634
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Therapy for Patients with a Tumor-Positive Resection Margin After Neoadjuvant Chemoradiotherapy and Esophagectomy.
van der Zijden CJ; van der Sluis PC; Mostert B; Nuyttens JJME; Spaander VMCW; Valkema R; Ruurda JP; Wijnhoven BPL; Lagarde SM
Ann Surg Oncol; 2024 Jun; 31(6):3813-3818. PubMed ID: 38245648
[TBL] [Abstract][Full Text] [Related]
3. Frequency of surgical resection after starting neoadjuvant chemoradiotherapy in patients with esophageal cancer: A population-based cohort study.
Borggreve AS; van Rossum PSN; Mook S; Haj Mohammad N; van Hillegersberg R; Ruurda JP
Eur J Surg Oncol; 2019 Oct; 45(10):1919-1925. PubMed ID: 30975447
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of circumferential resection margin in esophageal cancer with or without neoadjuvant chemoradiotherapy.
Liu CY; Hsu PK; Hsu HS; Wu YC; Chuang CY; Lin CH; Hsu CP
Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32065226
[TBL] [Abstract][Full Text] [Related]
5. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
[TBL] [Abstract][Full Text] [Related]
7. Techniques and short-term outcomes for total minimally invasive Ivor Lewis esophageal resection in distal esophageal and gastroesophageal junction cancers: pooled data from six European centers.
Straatman J; van der Wielen N; Nieuwenhuijzen GA; Rosman C; Roig J; Scheepers JJ; Cuesta MA; Luyer MD; van Berge Henegouwen MI; van Workum F; Gisbertz SS; van der Peet DL
Surg Endosc; 2017 Jan; 31(1):119-126. PubMed ID: 27129563
[TBL] [Abstract][Full Text] [Related]
8. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
[TBL] [Abstract][Full Text] [Related]
9. Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy.
Noordman BJ; van Klaveren D; van Berge Henegouwen MI; Wijnhoven BPL; Gisbertz SS; Lagarde SM; van der Gaast A; Hulshof MCCM; Biermann K; Steyerberg EW; van Lanschot JJB;
Ann Surg; 2018 May; 267(5):892-897. PubMed ID: 28350565
[TBL] [Abstract][Full Text] [Related]
10. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
[TBL] [Abstract][Full Text] [Related]
11. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
[TBL] [Abstract][Full Text] [Related]
13. Failure to Cure in Patients Undergoing Surgery for Esophageal Carcinoma: Hospital of Surgery Influences Prospects for Cure: A Nation-wide Cohort Study.
Voeten DM; van der Werf LR; Wijnhoven BPL; van Hillegersberg R; van Berge Henegouwen MI;
Ann Surg; 2020 Nov; 272(5):744-750. PubMed ID: 32657922
[TBL] [Abstract][Full Text] [Related]
14. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
[TBL] [Abstract][Full Text] [Related]
16. University hospital status and surgeon volume and risk of reoperation following surgery for esophageal cancer.
Kauppila JH; Wahlin K; Lagergren P; Lagergren J
Eur J Surg Oncol; 2018 May; 44(5):632-637. PubMed ID: 29548804
[TBL] [Abstract][Full Text] [Related]
17. Margin Positivity in Resectable Esophageal Cancer: Are there Modifiable Risk Factors?
Schlick CJR; Khorfan R; Odell DD; Merkow RP; Bentrem DJ
Ann Surg Oncol; 2020 May; 27(5):1496-1507. PubMed ID: 31933223
[TBL] [Abstract][Full Text] [Related]
18. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals.
Merkow RP; Bilimoria KY; McCarter MD; Chow WB; Ko CY; Bentrem DJ
Ann Surg Oncol; 2012 Feb; 19(2):357-64. PubMed ID: 21769460
[TBL] [Abstract][Full Text] [Related]
19. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.
Qin Q; Xu H; Liu J; Zhang C; Xu L; Di X; Zhang X; Sun X
Int J Surg; 2018 Nov; 59():11-18. PubMed ID: 30261331
[TBL] [Abstract][Full Text] [Related]
20. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
